Eli Lilly and Company's Fiscal Year is From January To December - All Figures are in USD, Billions.
The item "Change-In-Cash" stands at 6.42 Billion United States Dollars for the trailing twelve months (TTM) period ending 09/30/2025, the highest value at least since 03/31/2012, the period currently displayed.
Eli Lilly and Company's third quarter result of 6.42 Billion USD for the item "Change In Cash" represents an increase of 2,170.35 percent compared to it's second quarter result.
Also, Eli Lilly and Company's third quarter result of 6.42 Billion USD for the item "Change In Cash" represents an increase of 4,312.65 percent compared to it's third quarter result of last year.
Looking again at the trailing twelve months series (TTM), Eli Lilly and Company's third quarter result of 6.42 Billion USD for the item "Change In Cash" represents an increase of 4,117.27 percent compared to it's second quarter result.
Regarding the One-Year-Change of the series, the current value constitutes an increase of 5.43 Billion United States Dollars compared to the value the year prior.
The 1 year change is 5.43 Billion United States Dollars.
The 3 year change is 7.59 Billion United States Dollars.
The 5 year change is 4.39 Billion United States Dollars.
The 10 year change is 6.35 Billion United States Dollars.
| Logo | Name | Market Cap (USD) |
|---|---|---|
![]() | Johnson & Johnson - Change In Cash | 486,508,953,600.00 |
![]() | AbbVie Inc - Change In Cash | 399,570,305,024.00 |
![]() | Roche Holding AG - Change In Cash | 317,433,206,677.55 |
![]() | AstraZeneca PLC - Change In Cash | 280,205,508,085.11 |
![]() | Novartis AG - Change In Cash | 255,096,620,580.91 |